Heart failure or acute myocardial infarction with type 2 diabetes.
Conditions
Interventions
Group with miglitol first day
Group with miglitol second day
Sponsors
Jichi Medical University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Stable HF patients with NYHA II or above 2. Patients with AMI who have finished rehabilitation, and just before leaving hospital. 3. HbA1c level 6.5% (NGSP) or more, or diagnosed as diabetes, or taking antdiabetic medications. 4. Age more than 20 yrs.
Exclusion criteria
Exclusion criteria: 1. Patients with significant arrhythmia such as atrial fibrilation. 2. Patients with decompensated heart failure, fever, inflammation (CRP>1.0mg/dl) 3. Patients who are using insulin 4. Hepatic damage (AST, ALT >100 IU/L) 5. Patients with HBV, or HCV infection 6. Moderate renal dysfunction (serum creatinine >2.0mg/dl) 7. Patients with inflammatory bowel disease, colon ulcer, and bowel obstruction. 8. Severe chronic bowel diseases 9. Patients who have disease with increased bowel gas. 10. Patients with a history of gastric resection. 11. Lactose intolerance 12. Pregnant women or possible pregnancy. 13. Contraindication for miglitol 14. Dementia from whom we cannot obtain informed consent. 15. For whom the attending doctor considered he or she is not appropriate for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change in circadian blood glucose levels assessed by continuous glucose monitoring (CGM) 2. Arrhythmia, heart rate variability, and T-wave alternans (TWA) assessed by Holter ECG monitoring. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Blood pressure and heart rate variability evaluated by ABPM. Changes in circadian BP rhythm, BP level, and heart rate. | — |
Countries
Japan
Contacts
Public ContactKazuo Eguchi
Jichi Medical University School of Medicine Division of Cardiovascular Medicine, Department of Medicine
Outcome results
None listed